Faculty Bibliography

The efficacy and safety of liraglutide 3.0 mg vs. placebo, as adjunct to diet and exercise, was evaluated in racial subgroups. This post hoc analysis of pooled data from five double-blind randomized, placebo-controlled trials was conducted in 5325 adults with BMI >/=27 kg/m2 plus >/=1 comorbidity, or BMI >/=30 kg/m2 . Statistical interaction tests evaluated possible treatment effect differences between racial subgroups: White (4496, 84.4%), Black/African-American (550, 10.3%), Asian (168, 3.2%) and Other (111, 2.1%). Effects of liraglutide 3.0 mg on weight loss, associated metabolic effects and safety profile were generally consistent across racial subgroups. All achieved statistically significant mean weight loss at end-of-treatment with liraglutide 3.0 mg vs. placebo: White 7.7% vs. 2.3%, Black/African-American 6.3% vs. 1.4%, Asian 6.3% vs. 2.5%, Other 7.3% vs. 0.49%. Treatment effects on weight and cardiovascular risk markers generally showed no dependence on race (interaction-test p-values >0.05). Adverse events were comparable across racial subgroups.